Biocompatible Nanocarriers for Enhanced Oral Insulin Bioavailability: A Comprehensive Review

Abstract

Diabetes is a widespread disorder whose prevalence is constantly rising. Nanotechnology is at the forefront of technologies thought to be a beneficial tool for the early detection and treatment of diabetes. Researchers are constantly looking for more advanced approaches for the diagnosis and treatment of diabetes. New glucose monitoring technologies, delivery systems for insulin and other therapy are being developed by experts in the field of nanotechnology. Although improvements have been achieved in the delivery of insulin and the detection of glucose, this technology is still in its infancy. Although a variety of diseases have been diagnosed and treated with nanotechnology, the current study gives a brief update on the current state of nanotechnology's application in diagnosis and treatment of Diabetes.

           Recently, the use of nanotechnology has been successful in creating novel delivery systems that may increase the effectiveness of anti-diabetic medications. The two main stages that have received the most attention are (a) protecting the medicine by encapsulating it in a nano-carrier system, and (b) effectively releasing the drug in a controlled and progressive manner. Only a few studies in the literature, nevertheless, have used in vivo approaches to support these findings. Therapeutic nanocarrier development may improve patient compliance by boosting bioavailability, extending release, and hence lowering dose. The quality of life for diabetics may be considerably enhanced by this novel approach. The use of metal nanoformulations as indirect hypoglycemic agents is also described.

       Insulin therapy is an effective treatment for diabetes mellitus. Insulin plays a critical role in decreasing blood glucose levels in persons with type 1 diabetes, and it is also required in the later stages of type 2 diabetes. The most widely accepted type of insulin administration is parenteral administration; nevertheless, maintaining adequate glycemic control usually necessitates three to four daily insulin injections. In order to lessen discomfort, localised pain, annoyance, and infection, immunological reactions, and more acceptable alternative insulin administration techniques have been investigated due to lipoatrophy at the insulin injection site. Oral insulin administration mimics the physiology of endogenously generated insulin by transporting the medication straight into the liver via portal circulation. NPs, which are composed of naturally occurring biodegradable polymers, have been extensively studied in this area. They have emerged as possible carriers for a variety of therapeutic treatments, including controlled medication administration and insulin delivery via the oral route. Chitosan, alginate, dextran sulphate, and other naturally occurring water loving and water hating polymers used as oral insulin carriers have been extensively used to prepare NPs. Other insulin delivery ways includes artificial pancreases, nanopumps, insulin patch.

        Nanotechnology is extremely valuable in the field of diabetes, since it can aid in the diagnosis and treatment of the disease. It's assisting in the development of a new diabetes treatment strategy that involves glucose-responsive insulin therapy. When fully implemented, continuous glucose monitoring technologies and insulin administration systems such as an artificial pancreas will be beneficial to diabetes patients. Many people will be saved from hypoglycemia if there is no lag time between glucose measurement and insulin delivery, which can be achieved with nanotechnology. Non-invasive insulin delivery using various nanodrug delivery methods is currently being investigated and may become a reality in the near future. Nanotechnology is also assisting in the development of diabetes complications treatment techniques. Together, nanotechnology can help diabetic patients receive better care